Achiko Logo cropped.jpg
Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
May 17, 2022 07:30 ET | Achiko AG
Registered AptameX and Has Obtained a CE Mark, Allowing the Product to Be Sold in 27 Countries in the EUAptameX Has Unique Performance Advantages Over Other Rapid Tests Through its Use of DNA...
Dyadic Logo Current.jpg
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
May 09, 2022 08:30 ET | Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Achiko Logo cropped.jpg
AptameX Production and Commercialization Update
April 28, 2022 08:15 ET | Achiko AG
Company has commenced shipping and will book first sales in May 2022Reorganized production line able to meet stronger than expected demand for Achiko AG’s innovative DNA aptamer saliva-based rapid...
Achiko Logo cropped.jpg
Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
April 20, 2022 07:45 ET | Achiko AG
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
April 14, 2022 06:45 ET | BioNTech SE
Data from a subanalysis of 30 sera from a Phase 2/3 clinical trial of children 5 through 11 years of age show a 36-fold increase in SARS-CoV-2 Omicron neutralizing titers following a booster (third)...
Pfizer und BioNTech veröffentlichen Daten zu starker Immunantwort nach Auffrischungsimpfung mit dem COVID-19-Impfstoff bei Kindern im Alter von 5 bis 11 Jahren
April 14, 2022 06:45 ET | BioNTech SE
Daten einer Subanalyse mit 30 Seren aus einer klinischen Phase-2/3-Studie mit Kindern im Alter von 5 bis 11 Jahren zeigen einen 36-fachen Anstieg der neutralisierenden Antikörpertiter gegen die...
Dyadic Logo Current.jpg
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
April 13, 2022 08:52 ET | Dyadic International, Inc.
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to support Phase 1 and 2 clinical trials of Epygen’s...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
March 15, 2022 18:00 ET | BioNTech SE
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who...
Achiko Logo cropped.jpg
Achiko AG Production and Sales Update
March 03, 2022 07:30 ET | Achiko AG
Unique Chemistry with DNA Aptamers Completing Pre-Sales Validation TestingCompleting Pre-Sales Validation Testing in Indonesia ZURICH, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Ad...
Achiko Logo cropped.jpg
Achiko AG Research Paper and Commercialization Update
February 14, 2022 07:30 ET | Achiko AG
Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as “DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for...